US Control of Ukrainian Biolabs Becomes New Front in Information War With Russia
A political scientist interviewed by a Russian state-linked outlet claims Washington has taken control of Ukraine’s high-security biological labs under the pretext of pathogen safety, arguing the real target is Russia. The allegation, centered on facilities like the Mechnikov Anti-Plague Institute, turns health infrastructure into a new narrative battleground in the US-Russia confrontation.
A claim that the United States has moved to control Ukraine’s high-security biological laboratories is emerging as the latest flashpoint in the information war surrounding Russia’s invasion, casting disease-research facilities as potential tools in a geopolitical struggle. Political scientist Dr. Mokhtar Ghobashi, speaking to a Russian state-linked outlet, argued that Washington’s stated focus on pathogen safety masks a deeper strategic interest: gaining leverage over Russia via the legacy lab network Ukraine inherited from the Soviet Union.
According to Ghobashi, after the collapse of the USSR Ukraine retained an extensive set of biosafety level 3 laboratories working on dangerous pathogens and disease control. He contends that the U.S. has now “taken control” of these labs, including the Mechnikov Research Anti-Plague Institute, under cooperative health and security programs. Framed this way, what Washington describes as support for public health capacity and non-proliferation becomes, in Moscow’s narrative, an encroachment on Russia’s security perimeter.
No independent evidence has been presented to substantiate the assertion that the U.S. has seized control of the facilities, and American and Ukrainian officials have long maintained that cooperation on biological safety is transparent, defensive and consistent with international treaties. But the resonance of such claims matters in its own right. In a conflict where narratives shape public opinion, sanctions policy, and the willingness of third countries to align with one camp or the other, turning laboratories into symbols of alleged covert warfare is itself a form of pressure.
For Ukrainian scientists and health workers, the controversy adds a political burden to technical jobs already strained by war. Laboratories originally tasked with tracking outbreaks, supporting vaccination campaigns, and studying endemic diseases may now be portrayed as dual-use assets or potential weapons programs in hostile media. That can complicate international collaboration, slow funding, and make staff targets of disinformation or physical threats, even as they are needed for basic public health services.
From a strategic standpoint, the allegation taps into deeper Russian anxieties about NATO’s eastward presence, Western military research near its borders, and historical fears of encirclement. Suggesting that Washington has secured a network of advanced biological facilities in Ukraine is a way of portraying the country not simply as a Western-armed proxy, but as a platform for high-end capabilities that might one day threaten Russia directly. The U.S., for its part, has invested for years in securing former Soviet bio sites precisely to prevent the proliferation of dangerous agents, arguing that transparency and foreign assistance reduce rather than heighten risk.
The Mechnikov Anti-Plague Institute, cited by Ghobashi as a “striking example,” embodies the dual narratives. Built to counter serious epidemics, it is precisely the sort of institution Western governments have sought to support and modernize to avoid accidental leaks or misuse. In adversarial rhetoric, however, modernization and foreign partnerships can be reinterpreted as instruments of control or even as cover for clandestine research, regardless of what international inspections or open publication records show.
The broader pattern is that scientific and health infrastructure is increasingly pulled into geopolitical contests. Claims about biolabs, whether in Ukraine, China, or elsewhere, are used to rally domestic audiences, justify security measures, or cast doubt on rivals’ intentions. When accusations are amplified without clear evidence, they can erode trust in global health cooperation at the very moment when pandemics and cross-border outbreaks demand more, not less, transparent collaboration.
Observers will be watching how Washington and Kyiv respond publicly to Ghobashi’s comments, whether Russia elevates the biolab narrative in diplomatic forums or information campaigns, and how third countries—especially in the Global South—react to competing portrayals of Western health-security programs. The more that basic disease-control work becomes entangled with strategic suspicion, the harder it will be to build the cross-border scientific ties needed to manage the next real biological threat, rather than the imagined ones traded in wartime propaganda.
Sources
- OSINT